NovaBay Pharmaceuticals, Inc.
https://novabay.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From NovaBay Pharmaceuticals, Inc.
AstraZeneca Buys Into COVID-19 Antibodies From Newly Launched RQ Bio
The big pharma company and its new partner both expect demand to continue for pre-exposure prophylaxis antibody therapies, for COVID-19 and beyond.
Deal Watch: AZ, Alchemab To Study Immune Response For Novel Cancer Targets
Also, deals involving AbCellera/Angios, AstraZeneca/Alchemab, Kowa/Esteve, OSE/Veloxis, Tris/Park, Core One/Akome and Vertex/Obsidian.
Repeat Entrepreneurship And Talent Retention Key To Success Of SV Health Investors
In this latest installment of the VC Playbook series, In Vivo sits down with SV Health Investors’s Houman Ashrafian. The managing partner outlines the group’s investment philosophy, today’s skill set for VC success, and expectations for the future of Britain’s biotech industry post-Brexit and post-pandemic.
Finance Watch: Biotech Venture Capital Had Its Biggest Quarter Ever
Private Company Edition: VC mega-rounds boosted the Q1 2021 total. Also, new funds from Versant, The Column Group and Rapha Capital keep cash flowing into biopharma; up to $525m is invested in Exscientia; and Arch Oncology and Boundless Bio raised $105m each, while Forge brought in $120m.
Company Information
- Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- OTC, Consumer
-
Drug Delivery
- Site Specific
- Topical Delivery
- Other Names / Subsidiaries
-
- NovaCal Pharmaceuticals Inc.
- NovaBay® Pharmaceuticals, Inc